Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy
Unlike conventional antibodies, heavy chain only antibodies derived from camel contain a single variable domain (VHH) and two constant domains (CH2 and CH3). Cloned and isolated VHHs possess unique properties that enable them to excel conventional therapeutic antibodies and their smaller antigen-bin...
Main Authors: | Seyed Moein Moghimi, Fatemeh Rahbarizadeh, Davoud Ahmadvand, Ladan Parhamifar |
---|---|
Format: | Article |
Language: | English |
Published: |
Tabriz University of Medical Sciences
2013-01-01
|
Series: | BioImpacts |
Subjects: | |
Online Access: | http://dx.doi.org/10.5681/bi.2013.009 |
Similar Items
-
Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells
by: Anandani Nellan, et al.
Published: (2018-04-01) -
Effectiveness of 4-1BB-costimulated HER2-targeted chimeric antigen receptor T cell therapy for synovial sarcoma
by: Yudai Murayama, et al.
Published: (2021-12-01) -
The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2 in vitro and in Immune Competent Mice
by: Panyuan Li, et al.
Published: (2020-07-01) -
Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo
by: Yanjing Song, et al.
Published: (2017-03-01) -
Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an “Off-the-Shelf Immunotherapy” for Improvement in Cancer Treatment
by: Olaf Oberschmidt, et al.
Published: (2017-06-01)